Beyond its established glucose-lowering effects, metformin has also been shown to enhance GLP-1 secretion, potentially by delaying carbohydrate absorption and modulating DPP-4 activity, contributing to improved incretin responses in patients with type 2 diabetes (21). This evidence concerns the gene DPP4 and type 2 diabetes mellitus.